- FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations
- CheckMate 227 Reveals Tumour Mutational Burden as an Important and Independent Biomarker in Advanced NSCLC
- FDA Approves Nivolumab/Ipilimumab Combination for Intermediate or Poor-Risk Advanced RCC
- ESMO Immuno-Oncology Congress 2018: Abstracts
- FDA Finalises Guidances to Accelerate the Development of Reliable, Beneficial NGS-Based Tests
- EMA to Review Risk of Dosing Errors with Methotrexate
Oncology Articles
Oncology & Hematology Review. 2018;14(1):Epub ahead of print.
Oncology & Hematology Review. 2018;14(1):Epub ahead of print.
Oncology & Hematology Review. 2018;14(1): Epub ahead of print
Oncology & Hematology Review. 2018;14(1):Epub ahead of print.
European Oncology & Haematology. 2018;14(1):Epub ahead of print.
European Oncology & Haematology, 2018;14(1):Epub ahead of print
European Oncology & Haematology, 2018;14(1):[Online only]
European Oncology & Haematology. 2018;14(1):Epub ahead of print.
European Oncology & Haematology. 2018;14(1):Epub ahead of print.
Oncology & Hematology Review, 2017;14(1):[online only]
Oncology & Hematology Review, 2018;14(1): Epub ahead of print.
European Oncology & Haematology, 2017;13(2):147–51 DOI: https://doi.org/10.17925/EOH.2017.13.02.147
European Oncology & Haematology, 2017;13(2):134–8 DOI: https://doi.org/10.17925/EOH.2017.13.02.134
European Oncology & Haematology, 2017;13(2):120–6 DOI: https://doi.org/10.17925/EOH.2017.13.02.120
European Oncology & Haematology, 2017;13(2):102–7 DOI: https://doi.org/10.17925/EOH.2017.13.02.102
European Oncology & Haematology, 2017;13(2):101 DOI: https://doi.org/10.17925/EOH.2017.13.02.101
Oncology & Hematology Review, 2017;13(2):112–6 DOI: https://doi.org/10.17925/OHR.2017.13.02.112
Oncology & Hematology Review, 2017;13(2):107–11 DOI: https://doi.org/10.17925/OHR.2017.13.02.107
Oncology & Hematology Review, 2017;13(2):100–6 DOI: https://doi.org/10.17925/OHR.2017.13.02.100
Oncology & Hematology Review, 2017;13(2):92–9 DOI: https://doi.org/10.17925/OHR.2017.13.02.92